S2-E28 – SPECIAL EPISODE: What Can We Learn the Aldafermin Discontinuation In F2/F3 NASH?

Roger Green narrates a series of interviews, conversations and viewpoints about NGM Biopharmaceuticals discontinuing its F2/F3 aldafermin program

The SurfingNASH team weaves interviews, conversations and text notes from 9 stakeholders, including US and EU KOLs, program heads, treating physicians, patient advocates and NASH patients into a narrative addressing key issues. Was the ALPINE 2/3 trial a clinical failure? What commercial considerations might have played into NGM BIo’s decision? What lessons can we learn about clinical development strategies? NITs vs. biopsy? When to trust headlines and when not. There is a great deal to unpack in a 25-minute episode.

TOPICS: Diagnostics, Drugs, Patients, Policy and Perspectives Tags: 89bio, Akero Therapeutics, aldafermin, cirrhosis, Diabetes, Diagnostic Tests, drugstocks, efruxifermin, elafibranor, Fatty Liver, FDA, FGF-21, Fibrosis Level 3, Fibrosis Level 4, inventiva, lanifibranor, Madrigal, MRI-PDFF, NAFLD, NASH-TAG, NGM Biopharmaceuticals, non-invasive liver testing, Nordic Biosciences, Novo Nordisk, obeticholic acid, Phase3, Semaglutide, TrialDesign, resmetirom, primary endpoints, clinical development strategy,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast